University of Cambridge study shows how LLM GPT-4 can generate novel combinations of drugs not typically used to treat cancer ...

Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.

Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...

Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, ...

Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting ...

Researchers evaluated current treatment patterns and clinical outcomes for patients with HER2-positive metastatic breast cancer.